Catalyst Pharma files lawsuit against USFDA challenging approval of Ruzurgi

Ruzurgi was approved last month for treating Lambert-Eaton myasthenic syndrome that affects about one in 100,000 people in the United States.

U.S: Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for a rare neuromuscular disease.

Ruzurgi was approved last month for treating Lambert-Eaton myasthenic syndrome that affects about one in 100,000 people in the United States.

Read Also: Catalyst Pharma defends $375000 drug price after Bernie Sanders rebuke